Francisca Beato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francisca Beato has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Jason B. Fleming
Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA
13 shared publications - Aatur D. Singhi
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
10 shared publications - Alexandra F. Tassielli
Department of Gastrointestinal Surgical Oncology and Gastroenterology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
10 shared publications - Amir Mohammadi
Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida
10 shared publications - Cecilia G. Ethun
University of Texas Southwestern Medical Center Department of Surgery Dallas, TX
10 shared publications - Dina Alzhanova
Department of Surgery, University of Texas at Southwestern Medical Center, Dallas, Texas
10 shared publications
Latest Publications
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Generation of orthotopic mouse models of Smad4 mutant pancreatic cancer
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Generation of orthotopic mouse models of Smad4 mutant pancreatic cancer
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Immune landscape of SMAD4 WT and mutant human PDA
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Immune landscape of SMAD4 WT and mutant human PDA
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Loss of Smad4 alters the secretome of pancreatic cancer cells
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Loss of Smad4 alters the secretome of pancreatic cancer cells
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Inhibition of TGFb reduces survival in mice bearing 6620c1 orthotopic tumors
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Inhibition of TGFb reduces survival in mice bearing 6620c1 orthotopic tumors
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Transcriptomic and secretome analysis of Smad4 WT and Smad4-deficient PDAC cells
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Transcriptomic and secretome analysis of Smad4 WT and Smad4-deficient PDAC cells
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Loss of Smad4 alters the transcriptome of pancreatic cancer cells
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Loss of Smad4 alters the transcriptome of pancreatic cancer cells
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
TGFb gene family LOH and SMAD mosaicism
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
TGFb gene family LOH and SMAD mosaicism
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Inhibition of TGFb reduces IL-6 expression and STAT3 activation in PDAC
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Inhibition of TGFb reduces IL-6 expression and STAT3 activation in PDAC
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Data from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
The 5-year overall survival rate for pancreatic cancer remains ∼13%, underscoring the urgent need for improved treatment strategies. TGFβ is a promising target due to its significant involvement in the desmoplasia, immune suppression, and chemoresistance characteristics of pancreatic cancer. More than 300 clinical trials targeting TGFβ have been conducted in unselected patient cohorts; however, none of the therapies have gained FDA approval. Nevertheless, TGFβ blockade may hold promise for a subset of cancers with nonfunctional TGFβ signaling. More than 25% of pancreatic cancers carry mutations in SMAD4, a key component of canonical TGFβ signaling. In this study, we investigated the potential for stratifying patients based on SMAD4 mutational status to identify tumors susceptible to TGFβ inhibition. Analysis of SMAD4 expression in human pancreatic tumors revealed that SMAD4 mutation or loss is associated with worse disease-free survival. Intriguingly, intratumoral SMAD4 expression displayed heterogeneity among human pancreatic cancer samples. SMAD4-deficient genetically engineered mouse models and orthotopic SMAD4 knockout tumor models exhibited reduced survival, increased metastasis, and alterations in the tumor microenvironment compared with SMAD4 wild-type controls, consistent with gene and protein expression changes in the absence of functional SMAD4. Importantly, treating mice bearing SMAD4-deficient tumors with a blocking TGFβ antibody reduced tumor weight and improved survival. These findings suggest that genomic stratification by TGFβ axis alterations, such as SMAD4 mutations, may be a promising approach to identifying patients likely to benefit from a TGFβ inhibitor.Significance:Targeting TGFβ in pancreatic cancers that are deficient in canonical TGFβ signaling could provide a therapeutic strategy to enhance standard and immune therapy approaches for a substantial population of pancreatic cancer patients.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
The 5-year overall survival rate for pancreatic cancer remains ∼13%, underscoring the urgent need for improved treatment strategies. TGFβ is a promising target due to its significant involvement in the desmoplasia, immune suppression, and chemoresistance characteristics of pancreatic cancer. More than 300 clinical trials targeting TGFβ have been conducted in unselected patient cohorts; however, none of the therapies have gained FDA approval. Nevertheless, TGFβ blockade may hold promise for a subset of cancers with nonfunctional TGFβ signaling. More than 25% of pancreatic cancers carry mutations in SMAD4, a key component of canonical TGFβ signaling. In this study, we investigated the potential for stratifying patients based on SMAD4 mutational status to identify tumors susceptible to TGFβ inhibition. Analysis of SMAD4 expression in human pancreatic tumors revealed that SMAD4 mutation or loss is associated with worse disease-free survival. Intriguingly, intratumoral SMAD4 expression displayed heterogeneity among human pancreatic cancer samples. SMAD4-deficient genetically engineered mouse models and orthotopic SMAD4 knockout tumor models exhibited reduced survival, increased metastasis, and alterations in the tumor microenvironment compared with SMAD4 wild-type controls, consistent with gene and protein expression changes in the absence of functional SMAD4. Importantly, treating mice bearing SMAD4-deficient tumors with a blocking TGFβ antibody reduced tumor weight and improved survival. These findings suggest that genomic stratification by TGFβ axis alterations, such as SMAD4 mutations, may be a promising approach to identifying patients likely to benefit from a TGFβ inhibitor.Significance:Targeting TGFβ in pancreatic cancers that are deficient in canonical TGFβ signaling could provide a therapeutic strategy to enhance standard and immune therapy approaches for a substantial population of pancreatic cancer patients.
- Open Access
- 29 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (16) , 2987-2996
SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
The 5-year overall survival rate for pancreatic cancer remains ∼13%, underscoring the urgent need for improved treatment strategies. TGFβ is a promising target due to its significant involvement in the desmoplasia, immune suppression, and chemoresistance characteristics of pancreatic cancer. More than 300 clinical trials targeting TGFβ have been conducted in unselected patient cohorts; however, none of the therapies have gained FDA approval. Nevertheless, TGFβ blockade may hold promise for a subset of cancers with nonfunctional TGFβ signaling. More than 25% of pancreatic cancers carry mutations in SMAD4, a key component of canonical TGFβ signaling. In this study, we investigated the potential for stratifying patients based on SMAD4 mutational status to identify tumors susceptible to TGFβ inhibition. Analysis of SMAD4 expression in human pancreatic tumors revealed that SMAD4 mutation or loss is associated with worse disease-free survival. Intriguingly, intratumoral SMAD4 expression displayed heterogeneity among human pancreatic cancer samples. SMAD4-deficient genetically engineered mouse models and orthotopic SMAD4 knockout tumor models exhibited reduced survival, increased metastasis, and alterations in the tumor microenvironment compared with SMAD4 wild-type controls, consistent with gene and protein expression changes in the absence of functional SMAD4. Importantly, treating mice bearing SMAD4-deficient tumors with a blocking TGFβ antibody reduced tumor weight and improved survival. These findings suggest that genomic stratification by TGFβ axis alterations, such as SMAD4 mutations, may be a promising approach to identifying patients likely to benefit from a TGFβ inhibitor. Significance: Targeting TGFβ in pancreatic cancers that are deficient in canonical TGFβ signaling could provide a therapeutic strategy to enhance standard and immune therapy approaches for a substantial population of pancreatic cancer patients.
- 29 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (16) , 2987-2996
Open AccessSMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
The 5-year overall survival rate for pancreatic cancer remains ∼13%, underscoring the urgent need for improved treatment strategies. TGFβ is a promising target due to its significant involvement in the desmoplasia, immune suppression, and chemoresistance characteristics of pancreatic cancer. More than 300 clinical trials targeting TGFβ have been conducted in unselected patient cohorts; however, none of the therapies have gained FDA approval. Nevertheless, TGFβ blockade may hold promise for a subset of cancers with nonfunctional TGFβ signaling. More than 25% of pancreatic cancers carry mutations in SMAD4, a key component of canonical TGFβ signaling. In this study, we investigated the potential for stratifying patients based on SMAD4 mutational status to identify tumors susceptible to TGFβ inhibition. Analysis of SMAD4 expression in human pancreatic tumors revealed that SMAD4 mutation or loss is associated with worse disease-free survival. Intriguingly, intratumoral SMAD4 expression displayed heterogeneity among human pancreatic cancer samples. SMAD4-deficient genetically engineered mouse models and orthotopic SMAD4 knockout tumor models exhibited reduced survival, increased metastasis, and alterations in the tumor microenvironment compared with SMAD4 wild-type controls, consistent with gene and protein expression changes in the absence of functional SMAD4. Importantly, treating mice bearing SMAD4-deficient tumors with a blocking TGFβ antibody reduced tumor weight and improved survival. These findings suggest that genomic stratification by TGFβ axis alterations, such as SMAD4 mutations, may be a promising approach to identifying patients likely to benefit from a TGFβ inhibitor. Significance: Targeting TGFβ in pancreatic cancers that are deficient in canonical TGFβ signaling could provide a therapeutic strategy to enhance standard and immune therapy approaches for a substantial population of pancreatic cancer patients.